Suppr超能文献

咪达唑仑口服溶液用于儿童镇静催眠和抗焦虑的有效性及安全性:一项系统评价和Meta分析

Efficacy and Safety of Midazolam Oral Solution for Sedative Hypnosis and Anti-anxiety in Children: A Systematic Review and Meta-Analysis.

作者信息

Cheng Xiao, Chen Zhe, Zhang Lingli, Xu Peipei, Qin Fang, Jiao Xuefeng, Wang Yiyi, Lin Mao, Zeng Linan, Huang Liang, Yu Dan

机构信息

Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.

Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.

出版信息

Front Pharmacol. 2020 Mar 18;11:225. doi: 10.3389/fphar.2020.00225. eCollection 2020.

Abstract

Midazolam is recommended by health guidelines for sedation and hypnosis in children. Oral solution is a suitable dosage form for children. But there is no conclusive evidence for sedative-hypnosis and antianxiety effects by midazolam oral solution in children. Relevant studies were identified through searching PubMed, Embase, Cochrane Library, CINAHL, International Pharmaceuticals, four Chinese electronic databases, and relevant lists. Two reviewers independently selected trials, assessed trial quality, and extracted the data. Eighty-nine randomized controlled trials (RCTs) comparing midazolam oral solution with placebo or blank ( = 33), dexmedetomidine ( = 15), ketamine ( = 11), different midazolam doses ( = 10), midazolam injection ( = 8), chloral hydrate ( = 7), diazepam ( = 5), NO ( = 5), triclofos ( = 4), butorphanol ( = 2), fentanyl ( = 2), hydroxyzine ( = 1), and thiopental ( = 1) were identified. Meta-analysis showed no significant difference in the success rate and duration of sedation and hypnosis between midazolam oral and injectable solution ( > 0.05). The success rate of sedation and hypnosis of midazolam was higher than that of ketamine [risk ratio (RR) = 1.32, 95% CI (1.07, 1.62), = 0%, < 0.01]. No significant difference was found in the success rate of sedation and hypnosis, mask acceptance, and parental separation between midazolam oral solution and dexmedetomidine ( > 0.05), and the result of one cohort study was consistent. The results of RCTs and a prospective cohort study showed that the incidence of adverse drug reactions (ADR) was 19.57% (189/966). Incidence of adverse reactions between dose groups of (0.25, 0.5] and (0.5, 1.0] mg/kg was similar [Pf (95% CI) = 0.10 (0.04, 0.24) and Pf (95% CI) = 0.09 (0.02, 0.39), respectively], higher than that of the dose group of (0, 0.25] mg/kg [Pf (95% CI) = 0.01 (0.00, 0.19)]. Available evidence suggests that midazolam oral solution is as good as midazolam injection and dexmedetomidine and is better than ketamine. Based on efficacy and safety results, an oral midazolam solution dose of 0.5-1 mg/kg is recommended for children.

摘要

健康指南推荐咪达唑仑用于儿童镇静催眠。口服溶液是适合儿童的剂型。但尚无确凿证据表明咪达唑仑口服溶液对儿童有镇静催眠和抗焦虑作用。通过检索PubMed、Embase、Cochrane图书馆、CINAHL、国际药学数据库、四个中文电子数据库及相关列表确定了相关研究。两名评价者独立选择试验、评估试验质量并提取数据。共识别出89项随机对照试验(RCT),比较了咪达唑仑口服溶液与安慰剂或空白对照(n = 33)、右美托咪定(n = 15)、氯胺酮(n = 11)、不同剂量咪达唑仑(n = 10)、咪达唑仑注射液(n = 8)、水合氯醛(n = 7)、地西泮(n = 5)、氧化亚氮(n = 5)、三氯福司(n = 4)、布托啡诺(n = 2)、芬太尼(n = 2)、羟嗪(n = 1)和硫喷妥钠(n = 1)。荟萃分析显示,咪达唑仑口服溶液和注射溶液在镇静催眠成功率和持续时间上无显著差异(P>0.05)。咪达唑仑的镇静催眠成功率高于氯胺酮[风险比(RR)=1.32,95%置信区间(CI)(1.07,1.62),I² = 0%,P<0.01]。咪达唑仑口服溶液与右美托咪定在镇静催眠成功率、面罩接受度和家长分离方面无显著差异(P>0.05),一项队列研究结果与之相符。RCT和一项前瞻性队列研究结果显示,药物不良反应(ADR)发生率为19.57%(189/966)。剂量组(0.25,0.5]mg/kg和(0.5,1.0]mg/kg之间的不良反应发生率相似[Pf(95%CI)分别为0.10(0.04,0.24)和0.09(0.02,0.39)],高于剂量组(0,0.25]mg/kg[Pf(95%CI)=0.01(0.00,0.19)]。现有证据表明,咪达唑仑口服溶液与咪达唑仑注射液及右美托咪定效果相当,且优于氯胺酮。基于疗效和安全性结果,推荐儿童口服咪达唑仑溶液剂量为0.5 - 1mg/kg。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eccb/7093581/d12728382c5a/fphar-11-00225-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验